Lot numbers can be found on the outside label of a product:
CAS No. : 212844-53-6
|Size||Stock||Price||Quantity||Add to Cart||Quotation Online|
|Name:||Purvalanol A; NG-60|
|Cat. No. :||CS-4001|
|CAS No. :||212844-53-6|
|M. Wt. :||388.89|
|Solubility:||10 mM in DMSO|
Purvalanol A is a potent CDK inhibitor, which inhibits cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, cdk4-cyclin D1, and cdk5-p35 with IC50s of 4, 70, 35, 850, 75 nM, resepctively. IC50 & Target: IC50: 4 nM (cdc2-cyclin B), 70 nM (cdk2-cyclin A), 35 nM (cdk2-cyclin E), 850 nM (cdk4-cyclin D1), 75 nM (cdk5-p35) In Vitro: Purvalanol A inhibits cdc28 (S. cerevisiae) and erk1 with IC50s of 80 and 9000 nM. Purvalanol A shows inhibitory activities against the NCI panel of 60 human tumor cell lines, with average GI50 of 2 μM; two cell lines show an ∼20-fold increase in sensitivity to purvalanol A: the KM12 colon cancer cell line with a GI50 of 76 nM and the NCI-H522 non–small cell lung cancer cell line with a GI50 of 347 nM. Purvalanol A is a 2.5-fold more potent inhibitor of CDK2, but also inhibits DYRK1A potently and a number of other protein kinases in the low micromolar range. Purvalanol A inhibits MKK1, MAPK2/ERK2, JNK/SAPK1c with IC50s of 80, 26, 84 μM. Purvalanol A selectively inhibits the phosphorylation of cellular proteins. Purvalanol A prevents the increases of the contents of cyclins D and E during serum-induced G1 phase progression. Purvalanol A does not inhibit transcription under cell-free conditions.
Protocol:Cell assay  Cell lines were treated with purvalanol A, PP2, roscovitine or DMSO as a control. After 24 h, cells were collected, fixed in 70% ethanol and stained with propidium iodide. Acquisition was carried out on a FACS can flow cytometer (Becton Dickinson) to identify apoptotic cells with <2N DNA content. In addition, apoptosis was detected by Western blotting with anti-cleaved-caspase 3.
Bain J, et al. The specificities of protein kinase inhibitors: an update. Biochem J. 2003 Apr 1;371(Pt 1):199-204.
Gray NS, et al. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science. 1998 Jul 24;281(5376):533-8.
Villerbu N, et al. Cellular effects of purvalanol A: a specific inhibitor of cyclin-dependent kinase activities. Int J Cancer. 2002 Feb 20;97(6):761-9.
We apologize for the inconvenience. The Certificate of Analysis you requested is not currently available on-line:
1. The Lot Number you requested may have been entered incorrectly. How to get a Lot Number
2. The COA of the Lot you requested has not been added to our database.
|Tags:Purvalanol A supplier,Purvalanol A purchase,Purvalanol A manufacturer,Purvalanol A sigma,Purvalanol A distributor,cost,Purvalanol A buy,Purvalanol A for sale|